{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T01:40:01Z","timestamp":1779327601059,"version":"3.51.4"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pathological tau accumulates in the cerebral cortex of Parkinson's disease (PD), resulting in cognitive deterioration. Positron emission tomography (PET) can be used for <jats:italic>in vivo<\/jats:italic> imaging of tau protein. Therefore, we conducted a systematic review and meta-analysis of tau protein burden in PD cognitive impairment (PDCI), PD dementia (PDD), and other neurodegenerative diseases and explored the potential of the tau PET tracer as a biomarker for the diagnosis of PDCI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, the Cochrane Library, and Web of Science databases were systematically searched for studies published till 1 June 2022 that used PET imaging to detect tau burden in the brains of PD patients. Standardized mean differences (SMDs) of tau tracer uptake were calculated using random effects models. Subgroup analysis based on the type of tau tracers, meta-regression, and sensitivity analysis was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 15 eligible studies were included in the meta-analysis. PDCI patients (<jats:italic>n<\/jats:italic> = 109) had a significantly higher tau tracer uptake in the inferior temporal lobe than healthy controls (HCs) (<jats:italic>n<\/jats:italic> = 237) and had a higher tau tracer uptake in the entorhinal region than PD with normal cognition (PDNC) patients (<jats:italic>n<\/jats:italic> = 61). Compared with progressive supranuclear palsy (PSP) patients (<jats:italic>n<\/jats:italic> = 215), PD patients (<jats:italic>n<\/jats:italic> = 178) had decreased tau tracer uptake in the midbrain, subthalamic nucleus, globus pallidus, cerebellar deep white matter, thalamus, striatum, substantia nigra, dentate nucleus, red nucleus, putamen, and frontal lobe. Tau tracer uptake values of PD patients (<jats:italic>n<\/jats:italic> = 178) were lower than those of patients with Alzheimer's disease (AD) (<jats:italic>n<\/jats:italic> = 122) in the frontal lobe and occipital lobe and lower than those in patients with dementia with Lewy bodies (DLB) (<jats:italic>n<\/jats:italic> = 55) in the occipital lobe and infratemporal lobe.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:italic>In vivo<\/jats:italic> imaging studies with PET could reveal region-specific binding patterns of the tau tracer in PD patients and help in the differential diagnosis of PD from other neurodegenerative diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1145939","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T04:58:18Z","timestamp":1682571498000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Junjiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongning","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson Disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s12031-020-01776-5","article-title":"Tau in the pathophysiology of Parkinson's disease","volume":"71","author":"Pan","year":"2021","journal-title":"J Mol Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/fneur.2018.00809","article-title":"Tau pathology in Parkinson's disease","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain."},{"key":"B5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of A-Synuclein, Tau and amyloid-B pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat Rev Neurosci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.23736\/S1824-4785.17.03012-6","article-title":"Tau imaging with pet: an overview of challenges, current progress, and future applications","volume":"61","author":"Robertson","year":"2017","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1016\/j.jalz.2014.04.013","article-title":"In vivo tau imaging: obstacles and progress","volume":"10","author":"Villemagne","year":"2014","journal-title":"Alzheimers Dement."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3233\/JAD-160698","article-title":"Cross-sectional and longitudinal cognitive correlates of Fddnp Pet and Csf amyloid-B and Tau in Parkinson's disease","volume":"55","author":"Buongiorno","year":"2017","journal-title":"J Alzheimers Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","article-title":"The diagnosis of Parkinson's disease","volume":"5","author":"Tolosa","year":"2006","journal-title":"Lancet Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"Mds clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","article-title":"Assessment of 18f-Pi-2620 as a biomarker in progressive supranuclear palsy","volume":"77","author":"Brendel","year":"2020","journal-title":"JAMA Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/mds.26844","article-title":"Subcortical (18) F-Av-1451 binding patterns in progressive supranuclear palsy","volume":"32","author":"Cho","year":"2017","journal-title":"Mov Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00429-017-1507-y","volume":"223","author":"Coakeley","year":"2018","journal-title":"Brain Struct Funct."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1177\/0271678X16683695","article-title":"Positron emission tomography imaging of tau pathology in progressive supranuclear palsy","volume":"37","author":"Coakeley","year":"2017","journal-title":"J Cereb Blood Flow Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","article-title":"Tau positron emission tomographic imaging in the lewy body diseases","volume":"73","author":"Gomperts","year":"2016","journal-title":"JAMA Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/mds.26961","article-title":"In vivo cortical Tau in Parkinson's disease using 18f-Av-1451 positron emission tomography","volume":"32","author":"Hansen","year":"2017","journal-title":"Mov Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JAD-130032","article-title":"Pet imaging of neuropathology in tauopathies: progressive supranuclear palsy","volume":"36","author":"Kepe","year":"2013","journal-title":"J Alzheimers Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/mds.27252","article-title":"Distinct patterns of amyloid-dependent Tau accumulation in lewy body diseases","volume":"33","author":"Lee","year":"2018","journal-title":"Mov Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"646440","DOI":"10.3389\/fnagi.2021.646440","article-title":"Integrated (18)F-T807 Tau pet, structural MRI, and plasma Tau in tauopathy neurodegenerative disorders","volume":"13","author":"Li","year":"2021","journal-title":"Front Aging Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.28672","article-title":"Clinical utility of (18) F-Apn-1607 Tau pet imaging in patients with progressive supranuclear palsy","volume":"36","author":"Li","year":"2021","journal-title":"Mov Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fnagi.2019.00249","article-title":"Pet imaging of astrogliosis and Tau facilitates diagnosis of Parkinsonian syndromes","volume":"11","author":"Sch\u00f6necker","year":"2019","journal-title":"Front Aging Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ana.25060","volume":"82","author":"Schonhaut","year":"2017","journal-title":"Ann Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1038\/s41598-018-23041-x","volume":"8","author":"Smith","year":"2018","journal-title":"Sci Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18f]Flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"Jama."},{"key":"B28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ana.410070408","article-title":"Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations","volume":"7","author":"Boller","year":"1980","journal-title":"Ann Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s007020200027","article-title":"Impact of coexistent alzheimer pathology on the natural history of Parkinson's disease","volume":"109","author":"Jellinger","year":"2002","journal-title":"J Neural Transm (Vienna)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of A-synuclein and A\u03b2 in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00401-008-0347-5","article-title":"Prevalence and impact of vascular and alzheimer pathologies in lewy body disease","volume":"115","author":"Jellinger","year":"2008","journal-title":"Acta Neuropathol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau pet patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate Tau pet ligand 18f-Av-1451 recapitulate key features of braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain."},{"key":"B36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel Tau positron emission tomography tracer [F-18]-Av-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marqui\u00e9","year":"2015","journal-title":"Ann Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of Tau positron emission tomography tracer [(18)F]Av-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias","volume":"12","author":"Sander","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11910-019-0962-7","article-title":"Tau imaging in neurodegenerative diseases using positron emission tomography","volume":"19","author":"Wang","year":"2019","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B40","article-title":"First in human characterization of Pi-2620, a next generation pet tracer for assessing Tau in Alzheimer's disease and other tauopathies","author":"Seibyl","year":"2017","journal-title":"International Conference of Alzheimers and Parkinsons Disease"},{"key":"B41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","article-title":"Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies","volume":"17","author":"Stamelou","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of Av-1451 Tau pet in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","article-title":"Discovery and preclinical characterization of [(18)F]Pi-2620, a next-generation tau pet tracer for the assessment of Tau pathology in Alzheimer's disease and other tauopathies","volume":"46","author":"Kroth","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00259-019-04305-8","article-title":"Cross-interaction of tau pet tracers with monoamine oxidase b: evidence from in silico modelling and in vivo imaging","volume":"46","author":"Murugan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/brain\/awab120","article-title":"Discriminatory ability of next-generation Tau pet tracers for Alzheimer's disease","volume":"144","author":"Yap","year":"2021","journal-title":"Brain."},{"key":"B47","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/BF00304466","article-title":"Allocortical neurofibrillary changes in progressive supranuclear palsy","volume":"84","author":"Braak","year":"1992","journal-title":"Acta Neuropathol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with lewy bodies: third report of the Dlb consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-015-1406-3","article-title":"Neuropathologically mixed alzheimer's and lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes","volume":"129","author":"Walker","year":"2015","journal-title":"Acta Neuropathol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2967\/jnumed.117.197426","article-title":"Correlations of (18)F-Thk5351 pet with postmortem burden of Tau and astrogliosis in Alzheimer disease","volume":"59","author":"Harada","year":"2018","journal-title":"J Nucl Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-018-0556-7","article-title":"Neuroimaging-pathological correlations of [(18)F]Thk5351 pet in progressive supranuclear palsy","volume":"6","author":"Ishiki","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"B52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","article-title":"Monoamine oxidase B inhibitor, selegiline, reduces (18)F-Thk5351 uptake in the human brain","volume":"9","author":"Ng","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1093\/brain\/awx172","article-title":"Brain monoamine oxidase B and a in human Parkinsonian dopamine deficiency disorders","volume":"140","author":"Tong","year":"2017","journal-title":"Brain."},{"key":"B54","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/nan.12362","article-title":"Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type","volume":"43","author":"Brettschneider","year":"2017","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.mcn.2015.02.015","article-title":"The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to A-synuclein inclusions","volume":"65","author":"Radford","year":"2015","journal-title":"Mol Cell Neurosci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1145939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T04:58:22Z","timestamp":1682571502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1145939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":55,"alternative-id":["10.3389\/fneur.2023.1145939"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1145939","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"article-number":"1145939"}}